Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk’s (NVO) stock has dropped by 25% in March (on the Copenhagen exchange) to put it on track for its biggest ...

By Maggie Fick and Lucy Raitano LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for ...

CHICAGO -- Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring ...

Ozempic can lead to weight loss; however, intuitive eating advocates believe listening to your body’s hunger signals garner ...

Novo Nordisk NVO announced an update to the savings offer for its popular obesity injection, Wegovy (semaglutide). This ...

“Ozempic face” refers to the sagging of skin due to rapid weight loss. Experts say it’s preventable by slowing down weight ...

It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...